A Comparison of prasugrel at the time of percutaneous Coronary intervention or as pretreatment at the time of diagnosis in patients with non-ST-segment elevation myocardial infarction: Design and rationale for the ACCOAST study

American Heart Journal

Volumn 161, Issue 4, 2011, Pages

  Montalescot, Gilles ^a   Bolognese, Leonardo ^b   Dudek, Dariusz ^c   Goldstein, Patrick ^d   Hamm, Christian ^e   Tanguay, Jean Francois ^f   Ten Berg, Jur ^g   Widimsky, Petr ^h   Luo, Junxiang ⁱ   Miller, Debra L ⁱ   Goedicke, Jochen ^j  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b IRCCS POLICLINICO SAN DONATO   (Italy)

^c UNIVERSITY HOSPITAL IN KRAKOW   (Poland)

^d LILLE UNIVERSITY HOSPITAL   (France)

^e Kerckhoff Heart and Thorax Center   (Germany)

^f MONTREAL HEART INSTITUTE   (Canada)

^g ST ANTONIUS HOSPITAL   (Netherlands)

^h CHARLES UNIVERSITY   (Czech Republic)

ⁱ ELI LILLY AND COMPANY   (United States)

^j Lilly Research Laboratories   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; FIBRINOGEN RECEPTOR ANTAGONIST; PRASUGREL;

ANGIOCARDIOGRAPHY; ARTICLE; BLEEDING; COMPARATIVE STUDY; DOUBLE BLIND PROCEDURE; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; MULTICENTER STUDY (TOPIC); NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); STROKE; STUDY DESIGN;

EID: 79953726710     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2010.10.017     Document Type: Article

References (32)

1. Bassand J.P., Hamm C.W., and Ardissino D. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes: The Task Force for the Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of the European Society of Cardiology Eur Heart J 28 2007 1598 1660 (Pubitemid 47227122)
2. Yusuf S., Zhao F., and Mehta S.R. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation N Engl J Med 345 2001 494 502 (Pubitemid 32758501)
3. Mehta S.R., Yusuf S., and Peters R.J. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study Lancet 358 2001 527 533 (Pubitemid 32772726)
4. Szuk T., Gyongyosi M., and Homorodi N. Effect of timing of clopidogrel administration on 30-day clinical outcomes: 300-mg loading dose immediately after coronary stenting versus pretreatment 6 to 24 hours before stenting in a large unselected patient cohort Am Heart J 153 2007 289 295 (Pubitemid 46096860)
5. Topol E.J., Moliterno D.J., and Herrmann H.C. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization N Engl J Med 344 2001 1888 1894 (Pubitemid 32553357)
6. Steinhubl S.R., Berger P.B., and Mann J.T. III Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial JAMA 288 2002 2411 2420 (Pubitemid 35340537)
7. Steinhubl S.R., Berger P.B., and Brennan D.M. Optimal timing for the initiation of pre-treatment with 300 mg clopidogrel before percutaneous coronary intervention J Am Coll Cardiol 47 2006 939 943
8. Sabatine M.S., Hamdalla H.N., and Mehta S.R. Efficacy and safety of clopidogrel pretreatment before percutaneous coronary intervention with and without glycoprotein IIb/IIIa inhibitor use Am Heart J 155 2008 910 917
9. Widimsky P., Motovska Z., and Simek S. Clopidogrel pre-treatment in stable angina: for all patients >6 h before elective coronary angiography or only for angiographically selected patients a few minutes before PCI? A randomized multicentre trial PRAGUE-8 Eur Heart J 29 2008 1495 1503 (Pubitemid 351881978)
10. Kushner F.G., Hand M., and Smith S.C. Jr 2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients with ST-Elevation Myocardial Infarction (updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (updating the 2005 Guideline and 2007 Focused Update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Circulation 120 2009 2271 2306
11. Brandt J.T., Payne C.D., and Wiviott S.D. A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation Am Heart J 153 2007 66.e9 66.e16
12. Mega J.L., Close S.L., and Wiviott S.D. Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes Circulation 119 2009 2553 2560
13. Varenhorst C., James S., and Erlinge D. Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease Eur Heart J 30 2009 1744 1752
14. Mega J.L. ABCB1 genetic variants and cardiovascular outcomes following treatment with clopidogrel and prasugrel 2010 American College of Cardiology Atlanta (Ga) [abstract]
15. Wiviott S.D., Trenk D., and Frelinger A. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention Circulation 116 2007 2923 2932
16. Wiviott S.D., Braunwald E., and McCabe C.H. Prasugrel versus clopidogrel in patients with acute coronary syndromes N Engl J Med 357 2007 2001 2015 (Pubitemid 350106708)
17. Michelson A.D., Frelinger A.L. Jr, and Braunwald E. Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial Eur Heart J 30 2009 1753 1763
18. Chin C.T., Roe M.T., and Fox K.A. Study design and rationale of a comparison of prasugrel and clopidogrel in medically managed patients with unstable angina/non-ST-segment elevation myocardial infarction: the TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage Acute Coronary Syndromes (TRILOGY ACS) trial Am Heart J 160 2010 16 22.e1
19. Mehta S.R., Granger C.B., and Boden W.E. Early versus delayed invasive intervention in acute coronary syndromes N Engl J Med 360 2009 2165 2175
20. Montalescot G., Cayla G., and Collet J.P. Immediate vs delayed intervention for acute coronary syndromes: a randomized clinical trial JAMA 302 2009 947 954
21. Sorajja P., Gersh B.J., and Cox D.A. Impact of delay to angioplasty in patients with acute coronary syndromes undergoing invasive management analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial J Am Coll Cardiol 55 2010 1416 1424
22. Granger C.B., Goldberg R.J., and Dabbous O. Predictors of hospital mortality in the Global Registry of Acute Coronary Events Arch Intern Med 163 2003 2345 2353 (Pubitemid 37310196)
23. The Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO) Investigators An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction N Engl J Med 329 1993 673 682
24. Montalescot G., White H.D., and Gallo R. Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention N Engl J Med 355 2006 1006 1017 (Pubitemid 44343544)
25. 12 inhibitor, compared with clopidogrel in healthy humans Br J Clin Pharmacol 63 2006 421 430
26. 12 inhibitor: a multiple-dose study in healthy humans Platelets 17 2006 218 226 (Pubitemid 43890793)
27. Jakubowski J.A., Payne C.D., and Weerakkody G.J. Dose-dependent inhibition of human platelet aggregation by prasugrel and its interaction with aspirin in healthy subjects J Cardiovasc Pharmacol 49 2007 167 173 (Pubitemid 46579951)
28. Small D.S., Payne C.D., and Kothare P. Pharmacodynamics and pharmacokinetics of single doses of prasugrel 30 mg and clopidogrel 300 mg in healthy Chinese and white volunteers: an open-label trial Clin Ther 32 2010 365 379
29. Thygesen K., Alpert J.S., and White H.D. Universal definition of myocardial infarction Eur Heart J 28 2007 2525 2538 (Pubitemid 47616190)
30. Cutlip D.E., Windecker S., and Mehran R. Clinical end points in coronary stent trials: a case for standardized definitions Circulation 115 2007 2344 2351 (Pubitemid 46685903)
31. Kastrati A., Mehilli J., and Neumann F.J. Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial JAMA 295 2006 1531 1538
32. Giugliano R.P., White J.A., and Bode C. Early versus delayed, provisional eptifibatide in acute coronary syndromes N Engl J Med 360 2009 2176 2190